Menopausal Hormone Therapy: What We Know Now

Roush, Karen

doi:10.1097/01.naj.0000398539.52283.55

Cited by 3 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If HT is considered appropriate by the provider and desired by the patient, all concerns surrounding CBHT should be carefully reviewed together by both the patient and provider. Health care practitioners, including pharmacists, should also provide information on available nonhormonal options . Whether a patient chooses traditional manufactured or CBHT, the lowest dose for the shortest duration is preferred, with reassessment every 6 months to 1 year to minimize risks …”

Section: Resultsmentioning

confidence: 99%

Use of Compounded Bioidentical Hormone Therapy in Menopausal Women: An Opinion Statement of the Women's Health Practice and Research Network of the American College of Clinical Pharmacy

et al. 2014

View full text Add to dashboard Cite

Menopausal symptoms affect a significant portion of women. Traditional treatment with manufactured hormone therapy can alleviate these symptoms, but many women and their health care providers are concerned about the risks, such as venous thromboembolism and certain types of cancer, demonstrated with manufactured hormone therapy. Compounded bioidentical hormone therapy has been proposed and is often used as a solution for these concerns. Despite this use, no data are currently available to support the claims that compounded bioidentical hormone therapy is a safer or more efficacious option compared with manufactured hormone therapy. A common misperception is that all manufactured products consist of synthetic hormones and all compounded medications consist of natural hormones; however, in fact, significant overlap exists. Several key stakeholder organizations have issued statements expressing concern about the lack of evidence regarding the efficacy and safety of compounded bioidentical hormone therapy, in addition to concerns regarding prescribing patterns. The Women's Health Practice and Research Network of the American College of Clinical Pharmacy recommends against the consistent use of compounded bioidentical hormones as a safer option compared with manufactured therapy and supports the statements of other key organizations, acknowledging the need for more robust clinical studies to evaluate the potential advantages and disadvantages of compounded bioidentical products compared with manufactured products.

show abstract

Section: Resultsmentioning

confidence: 99%

Use of Compounded Bioidentical Hormone Therapy in Menopausal Women: An Opinion Statement of the Women's Health Practice and Research Network of the American College of Clinical Pharmacy

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Both soy and red clover supplement were found to have an almost equal impact on serum lipid levels. In postmenopausal women, total cholesterol, LDL cholesterol and triglyceride levels are increased and HDL cholesterol is decreased compared with premenopausal women of the same age and BMI [1,9]. Hormone replacement therapy has known to lower total and LDL cholesterol and to slightly increase HDL cholesterol, thus lowering the risk of cardiovascular disease in the postmenopausal period.…”

mentioning

confidence: 99%